In fact, no other clinical outcomes assessed in our cohort such as relapse, transplant-related mortality or GVHD, as well as infectious outcomes, specifically cytomegalovirus (CMV) disease, were influenced by RAGE or S100B polymorphisms (Figure S1). This evidence concerns the gene S100B and glycogen storage disease VI.